Table 4.
Correlation between disease duration, cumulative drug doses of cyclophosphamide and doxorubicin and post-transplant echocardiographic parameters.
| Variables | Disease duration | CD of cyclophosphamide | CD of doxorubicin | |||
|---|---|---|---|---|---|---|
| R | P value | R | P value | R | P value | |
| Conventional echo | ||||||
| LVIDs (mm) | 0.039 | 0.855 | 0.157 | 0.535 | 0.013 | 0.964 |
| LVIDd (mm) | 0.185 | 0.375 | 0.433 | 0.073 | 0.055 | 0.845 |
| EF (%) | 0.21 | 0.314 | – 0.565 | 0.015* | 0.203 | 0.467 |
| FS (%) | 0.02 | 0.994 | 0.265 | 0.288 | 0.506 | 0.054 |
| Speckle tracking | ||||||
| GLS Avg (%) | – 0.419 | 0.037* | – 0.654 | 0.003* | – 0.546 | 0.046* |
| Septal LS apex (%) | 0.446 | 0.096 | 0.188 | 0.452 | – 0.421 | 0.118 |
| Septal LS mid (%) | 0.421 | 0.118 | – 0.124 | 0.623 | – 0.351 | 0.20 |
| Septal LS base (%) | 0.351 | 0.20 | – 0.178 | 0.479 | – 0.198 | 0.478 |
| Lateral LS apex (%) | – 0.198 | 0.478 | – 0.284 | 0.523 | – 0.126 | 0.556 |
| Lateral LS mid (%) | 0.126 | 0.556 | 0.083 | 0.743 | – 0.452 | 0.091 |
| Lateral LS base (%) | 0.452 | 0.091 | – 0.397 | 0.103 | – 0.020 | 0.945 |
| 3D echo | ||||||
| EDVI (ml/m2) | 0.300 | 0.277 | 0.103 | 0.684 | 0.014 | 0.961 |
| ESVI (ml/m2) | 0.349 | 0.202 | 0.270 | 0.268 | 0.222 | 0.426 |
| 3D EF (%) | 0.447 | 0.045* | 0.407 | 0.044* | 0.654 | 0.048* |
| 3D SV (ml) | 0.247 | 0.243 | 0.211 | 0.401 | 0.044 | 0.878 |
Significant values are in [bold].
CD: cumulative dose, LVIDs: left ventricular internal dimension at end-systole, LVIDd: left ventricular internal dimension at end-diastole, EF: ejection fraction, FS: fractional shortening, GLS: global longitudinal strain, LVEDV left ventricular end-diastolic volume, 3D LVESV: left ventricular end-systolic volume, 3D EF: ejection fraction, SV: stroke volume, r: Pearson correlation, P: Probability.